BriaCell Therapeutics Corp.
NASDAQ: BCTX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- William V. Williams
- Employees
- 16
- Headquarters
- West Vancouver, Canada
- IPO year
- 2012
- Market cap
- $5.7M
- Website
- https://www.briacell.com
Loading BCTX…
Loading profile data…Frequently asked questions about BCTX
What does BriaCell Therapeutics Corp. (BCTX) do?
BriaCell Therapeutics Corp. is an immuno-oncology biotechnology company primarily focused on developing innovative immunotherapies to combat cancer. The firm's leading experimental drug, Bria-IMT, is currently undergoing Phase I/IIa clinical investigation. This crucial study evaluates its effectiveness when utilized in conjunction with immune ch...
Where does BCTX trade?
BriaCell Therapeutics Corp. (BCTX) trades on the NASDAQ Capital Market.
What sector is BCTX in?
BriaCell Therapeutics Corp. (BCTX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of BriaCell Therapeutics Corp.?
William V. Williams is the chief executive officer of BriaCell Therapeutics Corp. (BCTX).
Where is BriaCell Therapeutics Corp. headquartered?
BriaCell Therapeutics Corp. is headquartered in Canada.
Does BCTX pay a dividend?
BriaCell Therapeutics Corp. (BCTX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did BCTX go public?
BriaCell Therapeutics Corp. (BCTX) completed its initial public offering in 2012.